Lee Kyung-Hun相关文献与解析，生知库 | 链接生命科学的每一步

Park, Chan Soon; Ryu, Gangpyo; Ahn, Hyo-Jeong; Sun, Choonghyun; Lee, Seung-Pyo; Kim, Hyung-Kwan; Kim, Yong-Jin; Jeon, Sook Young; Lee, Han-Byoel; Moon, Hyeong-Gon; Han, Wonshik; Lee, Dae-Won; Lee, Kyung-Hun; Han, Sae-Won; Im, Seock-Ah; Lee, Sang Eun; Jaiswal, Siddhartha; Koh, Youngil; Park, Jun-Bean

毒理研究

发表日期：2026

文献求助收藏

Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases

曲妥珠单抗德鲁替康（T-DXd）联合脑立体定向放射外科手术对HER2阳性或低表达乳腺癌脑转移患者颅内控制率和放射性坏死风险的影响

期刊:Breast

影响因子:7.9

doi:10.1016/j.breast.2026.104751

Chun, Seok-Joo; Kim, Kyubo; Chang, Won Ick; Kim, Yong Bae; Paek, Sun Ha; Lee, Kyung-Hun; Song, Jin-Ho; Hong, Ji Hyun; Lee, Jieun; Jang, Won Il; Kim, Tae Hyun; Shin, Kyung Hwan

Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-marketing Surveillance Study in South Korea

在韩国开展的一项为期6年的上市后监测研究：艾立布林在既往接受过蒽环类和紫杉类药物治疗的晚期或转移性乳腺癌患者中的真实世界临床实践中的安全性和有效性

期刊:Cancer Research and Treatment

影响因子:3.8

doi:10.4143/crt.2024.1142

Chae, Yee Soo; Kwon, Kyung A; Lee, Moon Hee; Ahn, Mi Sun; Lee, Kyung-Hun; Koh, Su-Jin; Sohn, Joohyuk; Park, Keon Uk; Kim, Min Young; Pyo, Youngji; Kim, Bo Young; Jung, Kyung Hae

DNA Damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status.

曲妥珠单抗德鲁替康在HER2表达和同源重组缺陷状态不同的癌细胞中诱导DNA损伤和核异型性。

期刊:Cancer Research and Treatment

影响因子:3.8

doi:10.4143/crt.2025.201

Kim So Hyeon, Park Yoonjung, Min Ahrum, Park Hye Yeon, Kim Yu-Jin, Ham Sujin, Koh Jiwon, Kim Seongyeong, Lee Dae-Won, Ryu Han Suk, Kim Jin-Soo, Lee Kyung-Hun, Im Seock-Ah

Elimusertib, a Novel ATR Inhibitor, Induces Anti-tumor Effects through Replication Catastrophe in Breast Cancers.

Elimusertib 是一种新型 ATR 抑制剂，可通过乳腺癌中的复制灾难诱导抗肿瘤作用。

期刊:Cancer Research and Treatment

影响因子:3.8

doi:10.4143/crt.2024.1105

Kim Mudong, Min Ahrum, Kim Sohyeon, Kim Seongyeong, Kim Yu-Jin, Ham Sujin, Lee Miso, Lee Eunice Yoojin, Kim Jinyong, Lee Dae-Won, Lee Kyung-Hun, Im Seock-Ah

Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial

一项评估奈拉替尼和曲妥珠单抗生物类似药治疗HER2突变晚期实体瘤患者的安全性和有效性的II期研究：KCSG AL20-17/KM23试验

期刊:Cancer Communications

影响因子:24.9

doi:10.1002/cac2.70026

Lee, Kyoungmin; Lee, Kyung-Hun; Kim, Dong-Wan; Yoon, Jeesun; Choi, Yoon Ji; Lee, Soohyeon; Kim, Ju Won; Park, Kyong Hwa; Choi, Wonyoung; Lee, Youngjoo; Ryu, Hyewon; Koo, Dong-Hoe; Lee, YunGyoo; Jeung, Hei-Cheul; Lee, Min-Young; Lee, Namsu; Kang, Myoung Joo; Lee, Jieun; Hong, Sook Hee; Kang, Eun Joo; Park, In Hae

HER2

发表日期：2025

文献求助收藏

Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies

晚期肝细胞癌二线治疗：帕博利珠单抗：KEYNOTE-240 和 KEYNOTE-394 III 期研究的荟萃分析

期刊:Jhep Reports

影响因子:7.5

doi:10.1016/j.jhepr.2025.101350

Finn, Richard S; Gu, Kangsheng; Chen, Xi; Merle, Philippe; Lee, Kyung-Hun; Bouattour, Mohamed; Cao, Peiguo; Wang, Wei; Cheng, Ann-Lii; Zhu, Liangjun; Lim, Ho Yeong; Kudo, Masatoshi; Pan, Yueyin; Chang, Ting-Tsung; Edeline, Julien; Li, Wei; Yang, Ping; Li, Chen; Li, Jianfeng; Siegel, Abby B; Qin, Shukui

MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer.

MSN/STAT3 通过 IL-6/LPAR1 配体受体复合物驱动三阴性乳腺癌的干性和化疗耐药性

期刊:Breast Cancer Research

影响因子:5.6

doi:10.1186/s13058-025-02072-z

Lee Cheng Hyun, Park Soo Young, Lee Jae Seok, Kim Da Sol, Kim Ha Yeon, Song Min Ji, Im Seock-Ah, Lee Kyung-Hun, Lee Dae-Won, Nikas Ilias P, Koh Ji Won, Yang So Hyeon, Lee Hyebin, Ryu Han Suk

Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.

建立和表征 24 个乳腺癌细胞系和 3 个乳腺癌类器官，揭示了恶性胸腔积液衍生模型中的分子异质性和药物反应变异性

期刊:Breast Cancer Research

影响因子:5.6

doi:10.1186/s13058-025-02032-7

Kim Soon-Chan, Kim Ga-Hye, Park Jae-Hyeon, Lee Kyung-Hun, Koh Jiwon, Kim Tae-Yong, Lee Dae-Won, Kim Yu-Jin, Kim Seongyeong, Park Song-Yi, Min Ahrum, Shin Young-Kyoung, Im Seock-Ah, Ku Ja-Lok

Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer

细胞周期蛋白依赖性激酶9抑制剂诱导乳腺癌中转录-复制冲突和DNA损伤积累

期刊:Cancer Cell International

影响因子:5.3

doi:10.1186/s12935-025-03897-6

Minyoung Lee ，Kyung-Hun Lee ，Ahrum Min ，So Hyeon Kim ，Sujin Ham ，Hae Min Hwang ，Youlim Noh ，Yu-Jin Kim ，Dae-Won Lee ，Jiwon Koh ，Seock-Ah Im

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects

克隆性造血与曲妥珠单抗相关心脏毒性风险

Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases

曲妥珠单抗德鲁替康（T-DXd）联合脑立体定向放射外科手术对HER2阳性或低表达乳腺癌脑转移患者颅内控制率和放射性坏死风险的影响

Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-marketing Surveillance Study in South Korea

在韩国开展的一项为期6年的上市后监测研究：艾立布林在既往接受过蒽环类和紫杉类药物治疗的晚期或转移性乳腺癌患者中的真实世界临床实践中的安全性和有效性

DNA Damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status.

曲妥珠单抗德鲁替康在HER2表达和同源重组缺陷状态不同的癌细胞中诱导DNA损伤和核异型性。

Elimusertib, a Novel ATR Inhibitor, Induces Anti-tumor Effects through Replication Catastrophe in Breast Cancers.

Elimusertib 是一种新型 ATR 抑制剂，可通过乳腺癌中的复制灾难诱导抗肿瘤作用。

Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial

一项评估奈拉替尼和曲妥珠单抗生物类似药治疗HER2突变晚期实体瘤患者的安全性和有效性的II期研究：KCSG AL20-17/KM23试验

Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies

晚期肝细胞癌二线治疗：帕博利珠单抗：KEYNOTE-240 和 KEYNOTE-394 III 期研究的荟萃分析

MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer.

MSN/STAT3 通过 IL-6/LPAR1 配体受体复合物驱动三阴性乳腺癌的干性和化疗耐药性

Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.

建立和表征 24 个乳腺癌细胞系和 3 个乳腺癌类器官，揭示了恶性胸腔积液衍生模型中的分子异质性和药物反应变异性

Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer

细胞周期蛋白依赖性激酶9抑制剂诱导乳腺癌中转录-复制冲突和DNA损伤积累